Evidence map›Paper›PMID 36333865›Full record

ArticleBiotechnology and bioengineering2023

Comprehensive investigation of a structural variant in a bi-specific, N-and C-terminal Fc-fusion molecule, and its monitoring with LC-MS based method.

Antonio Datola, Abhijeet Satwekar, Nadine Barron, Sawako DeRosa, Brittany Tomascak, Jessica Dawson, Angelo Palmese, Mara Rossi

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Antonio DatolaAnalytical Development Biotech, Characterization & Innovative Analytics Unit, Global Healthcare Operations A business of Merck KGaA, Darmstadt, Germany.ORCID 0000-0002-4687-4358
Abhijeet SatwekarMerck Serono S.p.A., Rome, Italy.
Nadine BarronEMD Serono Research & Development Institute, Inc., EMD Serono, Billerica, Massachusetts, USA.
Sawako DeRosaEMD Serono Research & Development Institute, Inc., EMD Serono, Billerica, Massachusetts, USA.
Brittany TomascakEMD Serono Research & Development Institute, Inc., EMD Serono, Billerica, Massachusetts, USA.
Jessica DawsonEMD Serono Research & Development Institute, Inc., EMD Serono, Billerica, Massachusetts, USA.
Angelo PalmeseAnalytical Development Biotech, Characterization & Innovative Analytics Unit, Global Healthcare Operations A business of Merck KGaA, Darmstadt, Germany.
Mara RossiMerck Serono S.p.A., Rome, Italy.
Merck (Germany) · DEMerck Serono (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an increasing interest in the generation of Fc-fusion molecules to exploit the effector functions of Fc and the fusion partner, towards improving the therapeutic potential. The Fc-fusion molecules have unique structural and functional attributes that impart various advantages. However, the manufacturing of Fc-fusion molecules possesses certain challenges in the biopharmaceutical development. The fusion of unnaturally occurring two or more domains in a construct can pose problems for proper folding and are prone to aggregation and degradation. Reshuffling of disulfide bridges represents a posttranslational event that affects folding. This can play a critical role in the correct structure of a molecule and leads to structural heterogeneity in biotherapeutics; it may also impact the in vivo biological activities, safety, and efficacy of the biopharmaceutical. Our work presents an investigation case of a doublet band, as observed only in nonreducing sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) for a bi-specific, N- and C-terminal Fc-fusion molecule. Other characterization and orthogonal methods from the analytical panel did not indicate the presence of two distinct species, including the orthogonal CE-SDS (Caliper Lab Chip GXII). Therefore, it was necessary to determine if the phenomenon was an analytical artifact or a real variant of our Fc-fusion molecule. With the comprehensive mass spectrometry-based characterization, we were able to determine that the doublet band was related to the reshuffling of one disulfide bridge in one of the fused domains. Our work illustrates the application of nonreducing peptide mapping by mass spectrometry to characterize and identify disulfide variants in a complex N- and C-terminal Fc-fusion molecule, and further adoption to monitor the disulfide structural variants in the intermediate process samples to drive the manufacturing of a consistent product with the desired quality attributes.

Indexed as

Biological ProductsTandem Mass SpectrometryChromatography, LiquidDisulfidesBiological ProductsDisulfidesbi-specificFc-fusion proteinionic exchange chromatographymass spectrometrypeptide mappingreshuffled disulfide bondsSDS-PAGE

Identifiers

PMID36333865
PMCPMC10100451
OpenAlexW4308254652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.